CliffBio
small molecule

UBRELVY

UBROGEPANT

Loss of exclusivityDecember 2041latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameUBRELVY
Active ingredientUBROGEPANT
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusRX

Listed patents

PatentExpiresType
12329750December 2041use U-4213
11857542December 2041use U-3786
12194030December 2041use U-4122
11717515December 2041use U-3677
12458633January 2035product
11925709January 2035product
12168004January 2035product
10117836January 2035product
12310953January 2035product
12220408January 2035product
12458632January 2035product
8912210December 2033substance, product
8754096July 2032substance, product
9833448November 2031use U-2718
9499545November 2031substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

UBRELVY patent cliff — loss of exclusivity December 2041 | CliffBio